{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-25-014683","form_type":"8-K","ticker":"PGEN","cik":"0001356090","company_name":"PRECIGEN, INC.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.217382+00:00","generated_at":"2026-05-16T20:13:39.568879+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Precigen Reports Q3 2025 Financial Results; PAPZIMEOS Full FDA Approval in August","bullets":["PAPZIMEOS (zopapogene imadenovec-drba) received full FDA approval in August 2025 for adults with RRP.","Over 100 patients registered in PAPZIMEOS Patient Hub; more than 100 million lives covered by private insurance.","Submitted Marketing Authorization Application to EMA for zopapogene imadenovec in November 2025.","Cash, cash equivalents, and investments totaled $123.6 million as of September 30, 2025.","Entered credit facility providing up to $125 million non-dilutive financing; received first tranche of $100 million."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-25-014683","json":"https://secwatch.observer/filing/0000950103-25-014683.json","markdown":"https://secwatch.observer/filing/0000950103-25-014683.md","text":"https://secwatch.observer/filing/0000950103-25-014683.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356090/000095010325014683/0000950103-25-014683-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356090/000095010325014683/dp237316_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T20:13:39.568879+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}